420 related articles for article (PubMed ID: 33211297)
1. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
[TBL] [Abstract][Full Text] [Related]
2. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.
Durie BGM; Kumar SK; Ammann EM; Fu AZ; Kaila S; Lam A; Usmani SZ; Facon T
Adv Ther; 2024 May; 41(5):1923-1937. PubMed ID: 38494542
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Sim S; Quach H; Pham T; Smooker V; Filshie R
Intern Med J; 2024 Jan; 54(1):108-114. PubMed ID: 37357752
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries.
Abildgaard N; Anttila P; Waage A; Rubin KH; Ørstavik S; Bent-Ennakhil N; Gavini F; Ma Y; Freilich J; Hansson M
Eur J Cancer; 2024 Apr; 201():113921. PubMed ID: 38377776
[TBL] [Abstract][Full Text] [Related]
5. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
[TBL] [Abstract][Full Text] [Related]
6. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Gordan LN; Tan CR; Vescio R; Ye JC; Schinke C; Medhekar R; Fu AZ; Lafeuille MH; Thompson-Leduc P; Khare V; Reitan J; Milkovich G; Kaila S; Davies F; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):55-63. PubMed ID: 37838502
[TBL] [Abstract][Full Text] [Related]
7. Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting.
Cheong CS; Tengku K Aziz TAH; Anuar NA; Bee PC; Chin EFM; Khairullah S; Liong CC; Zamri Y; Gan GG
Asian Pac J Cancer Prev; 2024 Feb; 25(2):595-601. PubMed ID: 38415546
[TBL] [Abstract][Full Text] [Related]
8. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Cornell RF; D'Souza A; Kassim AA; Costa LJ; Innis-Shelton RD; Zhang MJ; Huang J; Abidi M; Aiello J; Akpek G; Bashey A; Bashir Q; Cerny J; Comenzo R; Diaz MA; Freytes C; Gale RP; Ganguly S; Hamadani M; Hashmi S; Holmberg L; Hossain N; Kamble RT; Kharfan-Dabaja M; Kindwall-Keller T; Kyle R; Kumar S; Lazarus H; Lee C; Maiolino A; Marks DI; Meehan K; Mikhael J; Nath R; Nishihori T; Olsson RF; Ramanathan M; Saad A; Seo S; Usmani S; Vesole D; Vij R; Vogl D; Wirk BM; Yared J; Krishnan A; Mark T; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2017 Feb; 23(2):269-277. PubMed ID: 27864161
[TBL] [Abstract][Full Text] [Related]
9. Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting.
Garrido D; Bove V; Villano F; Riva E
Acta Medica (Hradec Kralove); 2023; 66(3):117-121. PubMed ID: 38511422
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment.
Saeed N; Khan Z; Jehanzeb H; Shaikh T; Shaikh U; Adil SN; Madni V; Fatima H; Abiha UE; Ali N
Cureus; 2024 Apr; 16(4):e58999. PubMed ID: 38800157
[TBL] [Abstract][Full Text] [Related]
11. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].
Ma Y; Xiao XB; Chen XL; Yuan SZ; Lu Y; Zhao SH; Chen JL; Shi GN; Wang YQ; Cheng NN; Feng P; Ding MS; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1016-1021. PubMed ID: 38503525
[No Abstract] [Full Text] [Related]
12. VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study.
Nørgaard JN; Moore KLF; Slørdahl TS; Vik A; Tvedt THA; Schjesvold F
Blood Cancer J; 2024 Apr; 14(1):60. PubMed ID: 38594252
[No Abstract] [Full Text] [Related]
13. Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
Yokoyama A; Kada A; Saito AM; Sawamura M; Komeno T; Sunami K; Takezako N
Acta Med Okayama; 2019 Dec; 73(6):547-552. PubMed ID: 31871340
[TBL] [Abstract][Full Text] [Related]
14. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations.
Ravi G; Bal S; Joiner L; Giri S; Sentell M; Hill T; Godby KN; Costa LJ
Br J Haematol; 2024 Apr; 204(4):1300-1306. PubMed ID: 38291707
[TBL] [Abstract][Full Text] [Related]
15. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
Olszewski AJ; Dusetzina SB; Trivedi AN; Davidoff AJ
J Clin Oncol; 2018 Oct; 36(28):2879-2886. PubMed ID: 30113885
[TBL] [Abstract][Full Text] [Related]
16. Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757.
Blood; 2023 Mar; 141(10):1234. PubMed ID: 36893003
[No Abstract] [Full Text] [Related]
17. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2016 Jul; 91(7):719-34. PubMed ID: 27291302
[TBL] [Abstract][Full Text] [Related]
18. Chalazion in a patient with multiple myeloma treated with bortezomib.
Ghimire B; Hamajima Y; Carbajal-Carballo L; Anusim N
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593601
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria.
Korubo KI; Madu AJ; Okoye HC; Nwogoh B
J Glob Oncol; 2018 Sep; 4():1-7. PubMed ID: 30241144
[TBL] [Abstract][Full Text] [Related]
20. MCQs on Bortezomib-based induction therapy followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients: A single-center experience and review of Indian literature.
Dsouza H
Indian J Cancer; 2023 Oct; 60(4):570-571. PubMed ID: 38258871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
